Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares
I'm PortAI, I can summarize articles.
Syros Pharmaceuticals said Friday its board approved the voluntary delisting of shares from the Nasdaq Stock Market and the company has notified the exchange. The board also approved deregistration of common stock, which will terminate and suspend reporting obligations under the Securities and Exchange Act, according to the company. Syros said it plans to file a Form 25 with the US Securities and Exchange Commission to delist and deregister shares on or about March 10. The company expects that delisting will become effective on or about March 20.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments